International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19

Verena Börger; Daniel J. Weiss; Johnathon D. Anderson; Francesc E. Borràs; Benedetta Bussolati; David R. F. Carter; Massimo Dominici; Juan M. Falcón-Pérez; Mario Gimona; Andrew F. Hill; Andrew M. Hoffman; Dominique de Kleijn; Bruce L. Levine; Rebecca Lim; Jan Lötvall; S. Alex Mitsialis; Marta Monguió-Tortajada; Maurizio Muraca; Rienk Nieuwland; Anna Nowocin; Lorraine O'Driscoll; Luis A. Ortiz; Donald G. Phinney; Ilona Reischl; Eva Rohde; Ralf Sanzenbacher; Clotilde Théry; Wei Seong Toh; Kenneth W. Witwer; Sai Kiang Lim; Bernd Giebel

doi:10.1016/j.jcyt.2020.05.002

International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19

Verena Börger
, Daniel J. Weiss
, Johnathon D. Anderson
, Francesc E. Borràs
, Benedetta Bussolati
, David R. F. Carter
, Massimo Dominici
, Juan M. Falcón-Pérez
, Mario Gimona
, Andrew F. Hill
, Andrew M. Hoffman
, Dominique de Kleijn
, Bruce L. Levine
, Rebecca Lim
, Jan Lötvall
, S. Alex Mitsialis
, Marta Monguió-Tortajada
, Maurizio Muraca
, Rienk Nieuwland
, Anna Nowocin

Lorraine O'Driscoll, Luis A. Ortiz, Donald G. Phinney, Ilona Reischl, Eva Rohde, Ralf Sanzenbacher, Clotilde Théry, Wei Seong Toh, Kenneth W. Witwer^*, Sai Kiang Lim^*, Bernd Giebel^*

^*Corresponding author for this work

University of Duisburg-Essen
University of Vermont
University of California at Davis
Autonomous University of Barcelona
University of Turin
Oxford Brookes University
University of Modena and Reggio Emilia
CIC BioGUNE
CIBER - Center for Biomedical Research Network
Ikerbasque Basque Foundation for Science
Paracelsus Private Medical University
La Trobe University
University of Pennsylvania
University Medical Center Utrecht
Monash University
University of Gothenburg
Harvard University
University of Padua
Medicines and Healthcare Products Regulatory Agency
Trinity College Dublin
University of Pittsburgh
Scripps Research Institute
Austrian Agency for Health and Food Safety GmbH
Innsbruck Medical University
Paul-Ehrlich-Institut
Université PSL
National University of Singapore
Johns Hopkins University
Agency for Science, Technology and Research, Singapore

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.

Original language	English
Pages (from-to)	482-485
Number of pages	4
Journal	Cytotherapy
Volume	22
Issue number	9
Early online date	2020
DOIs	https://doi.org/10.1016/j.jcyt.2020.05.002
Publication status	Published - Sept 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 9 Industry, Innovation, and Infrastructure

Access to Document

10.1016/j.jcyt.2020.05.002

Fingerprint

Dive into the research topics of 'International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19'. Together they form a unique fingerprint.

Cite this

Börger, V., Weiss, D. J., Anderson, J. D., Borràs, F. E., Bussolati, B., Carter, D. R. F., Dominici, M., Falcón-Pérez, J. M., Gimona, M., Hill, A. F., Hoffman, A. M., de Kleijn, D., Levine, B. L., Lim, R., Lötvall, J., Mitsialis, S. A., Monguió-Tortajada, M., Muraca, M., Nieuwland, R., ... Giebel, B. (2020). International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. Cytotherapy, 22(9), 482-485. https://doi.org/10.1016/j.jcyt.2020.05.002

Börger, Verena ; Weiss, Daniel J. ; Anderson, Johnathon D. et al. / International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. In: Cytotherapy. 2020 ; Vol. 22, No. 9. pp. 482-485.

@article{8eed62ee499149bcbbe2fa156529f970,

title = "International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19",

abstract = "STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.",

author = "Verena B{\"o}rger and Weiss, \{Daniel J.\} and Anderson, \{Johnathon D.\} and Borr{\`a}s, \{Francesc E.\} and Benedetta Bussolati and Carter, \{David R. F.\} and Massimo Dominici and Falc{\'o}n-P{\'e}rez, \{Juan M.\} and Mario Gimona and Hill, \{Andrew F.\} and Hoffman, \{Andrew M.\} and \{de Kleijn\}, Dominique and Levine, \{Bruce L.\} and Rebecca Lim and Jan L{\"o}tvall and Mitsialis, \{S. Alex\} and Marta Mongui{\'o}-Tortajada and Maurizio Muraca and Rienk Nieuwland and Anna Nowocin and Lorraine O'Driscoll and Ortiz, \{Luis A.\} and Phinney, \{Donald G.\} and Ilona Reischl and Eva Rohde and Ralf Sanzenbacher and Clotilde Th{\'e}ry and Toh, \{Wei Seong\} and Witwer, \{Kenneth W.\} and Lim, \{Sai Kiang\} and Bernd Giebel",

year = "2020",

month = sep,

doi = "10.1016/j.jcyt.2020.05.002",

language = "English",

volume = "22",

pages = "482--485",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Informa Healthcare",

number = "9",

}

Börger, V, Weiss, DJ, Anderson, JD, Borràs, FE, Bussolati, B, Carter, DRF, Dominici, M, Falcón-Pérez, JM, Gimona, M, Hill, AF, Hoffman, AM, de Kleijn, D, Levine, BL, Lim, R, Lötvall, J, Mitsialis, SA, Monguió-Tortajada, M, Muraca, M, Nieuwland, R, Nowocin, A, O'Driscoll, L, Ortiz, LA, Phinney, DG, Reischl, I, Rohde, E, Sanzenbacher, R, Théry, C, Toh, WS, Witwer, KW, Lim, SK & Giebel, B 2020, 'International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19', Cytotherapy, vol. 22, no. 9, pp. 482-485. https://doi.org/10.1016/j.jcyt.2020.05.002

International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. / Börger, Verena; Weiss, Daniel J.; Anderson, Johnathon D. et al.
In: Cytotherapy, Vol. 22, No. 9, 09.2020, p. 482-485.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19

AU - Börger, Verena

AU - Weiss, Daniel J.

AU - Anderson, Johnathon D.

AU - Borràs, Francesc E.

AU - Bussolati, Benedetta

AU - Carter, David R. F.

AU - Dominici, Massimo

AU - Falcón-Pérez, Juan M.

AU - Gimona, Mario

AU - Hill, Andrew F.

AU - Hoffman, Andrew M.

AU - de Kleijn, Dominique

AU - Levine, Bruce L.

AU - Lim, Rebecca

AU - Lötvall, Jan

AU - Mitsialis, S. Alex

AU - Monguió-Tortajada, Marta

AU - Muraca, Maurizio

AU - Nieuwland, Rienk

AU - Nowocin, Anna

AU - O'Driscoll, Lorraine

AU - Ortiz, Luis A.

AU - Phinney, Donald G.

AU - Reischl, Ilona

AU - Rohde, Eva

AU - Sanzenbacher, Ralf

AU - Théry, Clotilde

AU - Toh, Wei Seong

AU - Witwer, Kenneth W.

AU - Lim, Sai Kiang

AU - Giebel, Bernd

PY - 2020/9

Y1 - 2020/9

N2 - STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.

AB - STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.

UR - https://www.scopus.com/pages/publications/85087294732

U2 - 10.1016/j.jcyt.2020.05.002

DO - 10.1016/j.jcyt.2020.05.002

M3 - Article

C2 - 32425691

SN - 1465-3249

VL - 22

SP - 482

EP - 485

JO - Cytotherapy

JF - Cytotherapy

IS - 9

ER -

Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussolati B, Carter DRF et al. International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. Cytotherapy. 2020 Sept;22(9):482-485. Epub 2020. doi: 10.1016/j.jcyt.2020.05.002

International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this